"A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer,"
"Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer,"
"Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF,"
"Orteronel for the treatment of prostate cancer,"
"Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen,"
"Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer,"
"Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation,"
"Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer study,"
"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase i/ii study,"
"Targeted MET inhibition in castration-resistant prostate cancer: A randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone,"
"Targeted therapy in prostate cancer: is there hope beyond the androgen receptor?,"
"Targeted therapy in prostate cancer: Is there hope beyond the androgen receptor?,"
"C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results,"
"Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers,"
"A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer,"
"A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma,"
"An epigenetic road to genome instability,"
"Androgen receptor antagonist prostate cancer therapy,"
"JAK and Jumonji: Deadly playmates,"
"A new "fix" for cancer,"
"A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy,"
"Abrogating angiogenesis just got EZier,"
"An expanded tumor playing field,"
"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes,"
"Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study,"
"DAMD to do better!,"
"Drugging bugs to make chemotherapy safer,"
"Emerging therapies in castrate-resistant prostate cancer,"
"Epigenetic regulation of androgen receptor signaling in prostate cancer,"
"Ez(H2) does it!,"
"Giving tumors the silent treatment,"
"Itraconazole: From histoplasmosis to hedgehog signaling,"
"Reducing the UnSIRTainty of Alzheimer's disease,"
"Sinking prostate cancer from under the sea,"
"Taking out the trash,"
"Thinking outside the box in prostate cancer,"
"TMPRSS2-ERG, a mover and a shaker,"
"Turning off the cancer switch,"
"Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6,"
"Through the looking glass,"
"Effect of DNA Methylation on Identification of Aggressive Prostate Cancer,"
"hADA2a and hADA3: new players in beta-catenin signaling.,"
"hADA2a and hADA3: New players in Î²-catenin signaling,"
"Early use of chemotherapy in conjunction with radical prostatectomy,"
"Surgery-associated factor VIII inhibitors in patients without hemophilia,"